Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06997081 · ClinicalTrials.gov registry record · Phase 2

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by University of Miami.

Recruiting
Registry status
Phase 2
Development phase
104
Enrollment target
1
Study location

NCT06997081 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 104 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06997081, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 2
Development phase
104 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Elranatamab

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2025-09-16
Est. Completion 2030-09-30
Phase Phase 2

Sponsor

University of Miami

721 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06997081

The ClinicalTrials.gov registry entry for NCT06997081 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT06997081 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06997081 about?

NCT06997081 is a clinical study titled "ERd Combination Treatment in Newly Diagnosed Multiple Myeloma". The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.

What is the current status of trial NCT06997081?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2025-09-16. Estimated completion is 2030-09-30.

What conditions does trial NCT06997081 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06997081?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Elranatamab (DRUG).

Who is sponsoring clinical trial NCT06997081?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06997081 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.